The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling

[1]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[2]  Charis Achilleos,et al.  Inflammation Shapes Stem Cells and Stemness during Infection and Beyond , 2016, Front. Cell Dev. Biol..

[3]  T. Visakorpi,et al.  Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers , 2016, Oncotarget.

[4]  Ruo-Pan Huang,et al.  Cytokines in cancer drug resistance: Cues to new therapeutic strategies. , 2016, Biochimica et biophysica acta.

[5]  Rong-jiang Wang,et al.  miR-135b inhibits tumour metastasis in prostate cancer by targeting STAT6 , 2015, Oncology letters.

[6]  H. Erb,et al.  Therapy escape mechanisms in the malignant prostate. , 2015, Seminars in cancer biology.

[7]  Joshua M. Stuart,et al.  A basal stem cell signature identifies aggressive prostate cancer phenotypes , 2015, Proceedings of the National Academy of Sciences.

[8]  F. Balkwill,et al.  Inflammation and cancer: advances and new agents , 2015, Nature Reviews Clinical Oncology.

[9]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[10]  M. Gilardi,et al.  Portrait of inflammatory response to ionizing radiation treatment , 2015, Journal of Inflammation.

[11]  W. Wagner,et al.  Interleukin-4 enhances PARP-dependent DNA repair activity in vitro. , 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[12]  B. Fingleton,et al.  IL4 receptor ILR4α regulates metastatic colonization by mammary tumors through multiple signaling pathways. , 2014, Cancer research.

[13]  Dinesh Vyas,et al.  Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis , 2014, OncoTargets and therapy.

[14]  R. Kofler,et al.  Development of a Multipurpose GATEWAY-Based Lentiviral Tetracycline-Regulated Conditional RNAi System (GLTR) , 2014, PloS one.

[15]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.

[16]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2014, European urology.

[17]  R. Bristow,et al.  HDAC inhibitor confers radiosensitivity to prostate stem-like cells , 2013, British Journal of Cancer.

[18]  N. Maitland,et al.  JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. , 2013, Cancer research.

[19]  G. Schäfer,et al.  IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9 , 2013, Endocrine-related cancer.

[20]  T. Pandita,et al.  The Role of Inflammatory Pathways in Cancer-Associated Cachexia and Radiation Resistance , 2013, Molecular Cancer Research.

[21]  N. Maitland,et al.  Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells , 2013, Nature Communications.

[22]  David L. Vaux,et al.  Research methods: Know when your numbers are significant , 2012, Nature.

[23]  H. Klocker,et al.  Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. , 2012, The American journal of pathology.

[24]  N. Maitland,et al.  Advanced prostate cancer—a case for adjuvant differentiation therapy , 2012, Nature Reviews Urology.

[25]  Z. Culig,et al.  Interleukin-6: A multifunctional targetable cytokine in human prostate cancer , 2012, Molecular and Cellular Endocrinology.

[26]  M. Frydenberg,et al.  Human Epithelial Basal Cells Are Cells of Origin of Prostate Cancer, Independent of CD133 Status , 2012, Stem cells.

[27]  Matthew J. Craig,et al.  IL‐4 induces proliferation in prostate cancer PC3 cells under nutrient‐depletion stress through the activation of the JNK‐pathway and survivin up‐regulation , 2012, Journal of cellular biochemistry.

[28]  S. Chowdhury,et al.  Clinical Investigation of the Role of Interleukin-4 and Interleukin-13 in the Evolution of Prostate Cancer , 2011, Cancers.

[29]  Y. Nagashima,et al.  Coexpression of aPKCλ/ι and IL‐6 in prostate cancer tissue correlates with biochemical recurrence , 2011, Cancer science.

[30]  M. Wicha,et al.  Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory Roots , 2011, Clinical Cancer Research.

[31]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[32]  Z. Culig.  Cytokine disbalance in common human cancers. , 2011, Biochimica et biophysica acta.

[33]  N. Maitland,et al.  Prostate Cancer Stem Cells: Do They Have a Basal or Luminal Phenotype? , 2011, Hormones & cancer.

[34]  N. Maitland,et al.  Cancer stem cells, models of study and implications of therapy resistance mechanisms. , 2011, Advances in experimental medicine and biology.

[35]  Ping Chen,et al.  Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention. , 2010, Neoplasia.

[36]  B. Fingleton,et al.  Epithelial interleukin-4 receptor expression promotes colon tumor growth. , 2010, Carcinogenesis.

[37]  Y. Chiba,et al.  Interleukin-4 upregulates RhoA protein via an activation of STAT6 in cultured human bronchial smooth muscle cells. , 2010, Pharmacological research.

[38]  R. Kutner,et al.  Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors , 2009, Nature Protocols.

[39]  Y. Chiba,et al.  A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. , 2009, American journal of respiratory cell and molecular biology.

[40]  S. Lang,et al.  Prostate cancer stem cells , 2009, The Journal of pathology.

[41]  A. Gao,et al.  Interleukin‐4 activates androgen receptor through CBP/p300 , 2008, The Prostate.

[42]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[43]  Q. Yuan,et al.  IL-4/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells. , 2008, Biochemical and biophysical research communications.

[44]  A. Gao,et al.  Interleukin‐4 stimulates androgen‐independent growth in LNCaP human prostate cancer cells , 2008, The Prostate.

[45]  M. Todaro,et al.  Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. , 2007, Cell stem cell.

[46]  Susobhan Das,et al.  Signal transducer and activator of transcription‐6 (STAT6) is a constitutively expressed survival factor in human prostate cancer , 2007, The Prostate.

[47]  S. Kuromitsu,et al.  Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl]amino}pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors. , 2007, Bioorganic & medicinal chemistry.

[48]  C. Reddy,et al.  Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. , 2006, Urology.

[49]  N. Maitland,et al.  Prostate cancer stem cells. , 2006, European journal of cancer.

[50]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.

[51]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[52]  M. Sadar,et al.  Interleukin-4 in patients with prostate cancer. , 2005, Anticancer research.

[53]  Xin Lin,et al.  Requirement for NF‐κB in interleukin‐4‐induced androgen receptor activation in prostate cancer cells , 2005 .

[54]  M. Kornmann,et al.  Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions , 2005, British Journal of Cancer.

[55]  Xin Lin,et al.  Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. , 2005, The Prostate.

[56]  D. Neal,et al.  CD133, a novel marker for human prostatic epithelial stem cells , 2004, Journal of Cell Science.

[57]  G. Stassi,et al.  IL-4 Protects Tumor Cells from Anti-CD95 and Chemotherapeutic Agents via Up-Regulation of Antiapoptotic Proteins1 , 2004, The Journal of Immunology.

[58]  William C Hahn,et al.  Lentivirus-delivered stable gene silencing by RNAi in primary cells. , 2003, RNA.

[59]  R. Puri,et al.  Interleukin-4 receptor-targeted cytotoxin therapy of androgen-dependent and -independent prostate carcinoma in xenograft models. , 2003, Molecular cancer therapeutics.

[60]  J. Berzofsky,et al.  Resistance to Metastatic Disease in STAT6-Deficient Mice Requires Hemopoietic and Nonhemopoietic Cells and Is IFN-γ Dependent1 , 2002, The Journal of Immunology.

[61]  Rajiv Dhir,et al.  Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. , 2002, The Journal of urology.

[62]  D. Neal,et al.  Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. , 2001, Journal of cell science.

[63]  H. Klocker,et al.  Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[64]  G. Wise,et al.  Cytokine variations in patients with hormone treated prostate cancer. , 2000, Journal of Urology.

[65]  P. Rothman,et al.  IL-4/IL-13 signaling beyond JAK/STAT. , 2000, The Journal of allergy and clinical immunology.

[66]  W. Paul,et al.  The IL-4 receptor: signaling mechanisms and biologic functions. , 1999, Annual review of immunology.

[67]  S Detre,et al.  A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. , 1995, Journal of clinical pathology.

[68]  W. Paul,et al.  Acquisition of lymphokine-producing phenotype by CD4+ T cells. , 1994, Annual review of immunology.

[69]  J. Lowenthal,et al.  Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hemopoietic and nonhemopoietic cells. , 1988, Journal of immunology.

[70]  W. Paul,et al.  Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage , 1987, Nature.

[71]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.